

Index

A

- Actinomycosis, 387
- Acute pelvic pain, *see* Pelvic pain
- ADC, *see* Apparent diffusion coefficient maps
- Adenocarcinoma, 357
 - cervical cancer, 119, 139
- Adenoma malignum, 119
- Adenomyosis, 450
 - clinical presentation, 85–86
 - CT appearance, 101–103
 - diagnosis, 84
 - diagnostic imaging, 88–89
 - epidemiology, 84
 - histopathology, 84–85
 - hysterectomy, 86
 - macroscopic pathology, 84, 85
 - MRI imaging
 - criteria, 98–99
 - differential diagnosis, 101
 - growth patterns, 100
 - imaging characteristics, 100
 - locations, 100
 - nonneoplastic condition, 84
 - pathogenesis, 84
 - premenopausal women, 84
 - therapy, 86
 - tissue injury and repair, 84
 - UAE, 103–108
 - uterus-conserving surgery, 86
- Adenosarcoma, uterine sarcomas
 - low-grade malignant, 210–211
 - mixed epithelial-mesenchymal origin, 211
 - MR imaging, 219, 221
 - prognosis, 222
 - sonographic features, 219
 - staging system, 212
- Adnexal masses
 - MR imaging
 - histopathological diagnosis, 276–284
 - IOTA group, 275
 - malignancy risk, 276, 277
 - pelvis, 274–276, 285
 - with ultrasonographic patterns, 274–275
 - ovarian benign lesions
 - in adolescents, 267–268
 - brenner tumors, 263–266
 - in children, 267–268
 - CT, 244
 - cystadenofibroma, 255–256
 - cystadenoma (*see* Cystadenoma)
 - DWI, 242–244
 - vs.* extraovarian mass, 246
 - fast spin echo sequences, 242
 - in females, 267–268
 - functioning ovarian tumor, 266–267
 - mature teratoma (*see* Teratoma)
 - MRI, 242
 - origin, 244–246
 - ovarian cysts (*see* Ovarian cysts)
 - sex cord-stromal tumors (*see* Sex cord-stromal tumors)
 - turbo spin echo sequences, 242
 - in pregnancy, 268–269
 - preoperative imaging, 241
 - with solid tissue, 283
 - without solid tissue, 278
- Aggressive angiomyxoma, 363, 365
- Amenorrhea, 443
- Anatomy, female pelvis, 1
 - anal sphincter complex, 2, 7
 - anococcygeal body, 2, 3
 - anorectum, 2, 4, 11
 - anterior compartment, 2
 - connective tissue structures, 19–20
 - external urethral sphincter, 20, 21
 - levator ani muscle, 20
 - lymphatics, 22
 - paravisceral space, 22
 - pubococcygeus and puborectalis muscle, 20
 - reinterpreted anatomy and clinical relevance, 22
 - striated muscles, 20
 - urethral ligaments, 20, 21
 - vessels and nerves, 22
 - broad ligament, 2, 9
 - clinical subdivision, 2
 - functional and clinical requirements, 2

- Anatomy, female pelvis (*cont.*)
 inferior hypogastric plexus, 2, 6
 levator ani muscle, 2, 8
 mesometrium, 2, 10
 mesosalpinx, 2, 10
 mesovarium, 2, 10
 middle compartment, 2
 connective tissue structures, 22–25
 connective tissue, uterus and vagina, 25–26
 levator ani muscle, 25
 lymphatics, 26
 paracervical and paravaginal tissue, 22, 23
 rectovaginal fascia/septum, 24
 reinterpreted anatomy and clinical relevance, 25–26
 subperitoneal connective tissue and nerve vessel-guiding plate, 24
 supportive ligaments, 26
 vessels and nerves, 26
 paravisceral fat pad, 2, 9
 pelvic floor muscles, 2, 11
 perineal body, 2, 3
 perineal membrane, 2, 4
 perirectal compartment, 2, 5
 perirectal tissue, 12, 13
 posterior compartment, 2
 anal sphincter complex, 17, 18
 anorectum, 2, 4, 11
 computer-assisted reconstructions, 14, 17
 connective tissue structures, 11–14
 levator ani muscle, 14, 15
 lymphatics, 19
 nerves and vessels, 19
 pelvic floor muscles, 2, 11
 perirectal tissue, 12, 13
 presacral (sub) compartment, 2, 5, 12, 13
 presacral fascia, 2, 5, 11
 puborectalis muscle, 14, 16
 rectal adventitia, 12
 rectal fascia, 2, 6, 13
 rectoceles, 19
 rectovaginal fascia, 2, 7, 14
 reinterpreted anatomy and clinical relevance, 17, 19
 sphincter ani externus, 14
 presacral (sub) compartment, 2, 5, 12, 13
 presacral fascia, 2, 5, 11
 pubovesical ligament, 2, 7
 rectal adventitia, 12
 rectal fascia, 2, 6, 13
 rectouterine fold, 2, 9
 rectouterine pouch, 2, 9
 rectovaginal fascia, 2, 7, 14
 tendinous arch, pelvic fascia, 2, 8
 transverse cervical/cardinal ligament, 2, 10
 uterosacral ligament, 2, 6
 vesicouterine fold, 2, 10
 vesicouterine pouch, 2, 10
- Android pelvis, 458
 Annular placenta, 473
 Anococcygeal ligament, 416
 Antepartum hemorrhage, 477
 Anthropoid pelvis, 458
 Antiperistaltic agents, 372
 Apparent diffusion coefficient maps (ADC), 307, 371, 373, 374
 Appendicitis, 397–398
 Arcuate uterus, 72, 73, 449
 Aromatase theory, 326
 Arterial spin labeling (ASL), 482
 Asherman syndrome, 432, 435
- B**
 Bartholin gland cyst, 351–352
 Bartholinitis, 351
 Battledore placenta, 473
 Benign massive edema, 390
 Benign teratoma, Malignant transformation in, 312–313
 Bicornuate uterus, 67, 70, 447–448
 Bilateral hydrosalpinx, 442
 Bilateral ovarian adenocarcinoma, 374
 Bilateral ovarian cancer, 290, 291, 328, 329
 Bilateral tubo-ovarian abscess, 386
 Bladder endometriosis, 327
 Borderline tumors (BT)
 differential diagnosis, 308
 histologic and cytogenetic features, 306
 imaging findings, 307–308
 mucinous, 307
 Brenner tumors, 263–266
 BT, *see* Borderline tumors
- C**
 CA-125, 290, 308, 309
Candida albicans, 171
 Carcinoid tumors, 260
 Carcinosarcomas
 endometrial cancer, 182
 uterine sarcomas, 211
 Cardiophrenic lymph nodes, 301, 370
 Cell-free fetal DNA, 482
 Cephalopelvic disproportion, 457–458
 Cervical cancer
 benign lesions
 cervicitis, 171–172
 ectopic cervical pregnancy, 172
 endometriosis, 172
 leiomyoma, 171
 nabothian cyst, 169, 171
 polyps, 171
 rare benign tumors, 171
 central pelvic recurrence, 122
 clinical symptoms, 119
 cytology screening tests, 118–119
 distant metastasis, 122
 FIGO staging, 120–121
 growth patterns, 121–122
 hematogenous dissemination, 122

- histopathology, 119–120
- HPV vaccination, 119
- incidence, 117–118
- lymph node metastasis, 121–122
- malignant tumors
 - lymphoma, 171
 - malignant melanoma, 171
 - metastasis, 170
- MRI (*see* Magnetic resonance imaging (MRI))
- Pap smear test, 118
- pathogenesis, 118
- PET/CT, 170
- prognosis, 124–125
- recurrence
 - adrenal metastases, 155
 - after hysterectomy, 165
 - after radiochemotherapy, 167, 170
 - after surgery, 169
 - bone metastases, 154
 - CT, 168
 - follow-up examinations, 165–166
 - MRI, 168
 - of pelvic sidewall, 166, 170
 - PET-CT, 168
 - pulmonary metastases, 153
- staging
 - distant metastases, 152–155, 158–159
 - lymph node, 146–147, 149–152, 154–157
 - MR general appearance, 137–139
 - rare histologic types, 139–140
 - stage IA, 140–141
 - stage IB, 141–144
 - stage IIA, 141, 145–147
 - stage IIB, 142–143, 148–151
 - stage IIIA, 143–144
 - stage IIIB, 144–145, 151
 - stage IVA, 145, 152–154
 - stage IVB, 146
 - tumor size, 140
- treatment
 - adjuvant radiochemotherapy, 123
 - chemoradiotherapy, 122, 124
 - FIGO IB-IVA, 123–124
 - FIGO stage IA1 disease, 122
 - FIGO stage IA2/IB1 lesions, 122–123
 - lymph node dissection, 123
 - neoadjuvant radiochemotherapy, 123
 - operative techniques, 123
 - during pregnancy, 124
 - radiotherapy, 124
 - of recurrent disease, 124
 - therapies, 124
 - ultrasonography, 170
- Cervical intraepithelial neoplasia (CIN), 118
- Cervix
 - CT, 56, 57
 - dynamic enhancement patterns, 57
 - MRI, 57, 58
 - Müllerian ductal fusion, 58
 - nabothian cysts, 57, 58
 - plicae palmatae, 58
 - zonal anatomy, 57
- Chlamydia trachomatis* infection, 171, 384
- Chorioangiomas, 480
- Chronic salpingitis, 393
- Circumvallate placenta, 473
- Clear cell carcinomas, 180, 181, 305
- Colon adenocarcinoma, 361–362
- Colon cancer metastases, 317, 319
- Colonic diverticulosis, 398–399
- Color Doppler ultrasound, 437, 480
 - endometriosis, 326, 327
 - ovarian vein thrombosis, 396
- Colo-vesical fistula, 399
- Colpocystoproctography, 409, 424
- Colpocystorectography, 425
- Computed tomography (CT), 38, 353
 - acute appendicitis, 397, 398
 - adenomyosis, 101–103
 - cervical cancer
 - distant metastases, 158
 - imaging before radiotherapy, 156, 160
 - indications, 125
 - lymph node staging, 157
 - vs.* MRI, 126–127
 - for recurrent, 168
 - chest, 153
 - Crohn's disease, 401, 402
 - disadvantages, 40
 - diverticulosis, 399
 - epiploic appendages, 400
 - filtered back projection, 40
 - hydrosalpinx, 385
 - intravenous iodine-based contrast media, 41–42
 - leiomyomas, 101–103
 - lymph node imaging
 - in benign and malignant lymph nodes, 373–376
 - indications and value of imaging, 370, 373
 - motion artifacts, 38
 - multidetector scan, 38
 - oral and rectal contrast media, 40–41
 - ovarian cancer, 295
 - brenner tumors, 263
 - BT, 307
 - cystadenofibroma, 255–256
 - cystadenoma, 252–254
 - dysgerminoma, 311, 312
 - epithelial ovarian cancer, 305
 - fallopian tube cancer, 319
 - FIGO classification system, 298–301
 - immature teratoma, 312
 - lymphomas, 316
 - mature cystic teratomas, 257
 - ovarian leiomyoma, 284
 - recurrent ovarian cancer, 308–310
 - resectability prediction, 301, 302
 - struma ovarii, 260
 - theca lutein cysts, 250, 251
 - value of imaging, 301

Computed tomography (CT) (*cont.*)

- ovarian cysts, 382, 383
 - ovarian torsion, 390–392
 - ovaries
 - broad ligament and, 233
 - normal peri- and postmenopausal, 230–231
 - ovarian transposition, 236–238
 - in reproductive age, 227–228, 230
 - veins, 233, 235
 - vessels in retroperitoneum and suspensory ligament, 233, 234
 - patient preparation and positioning, 40
 - pelvic congestion syndrome, 394–396
 - pelvic pain disorders, 382
 - photon starvation effect, 40
 - PID, 384
 - primary vaginal carcinoma, 355
 - protocol, 64-detector scanner, 38, 40
 - radiation reduction and protection, 40
 - rectus sheath hematoma, 402
 - speed of, 38
 - TOA, 388
 - vaginal and vulvar diseases, 345–346
 - volume coverage, 38
 - X-ray tubes, 38
- Congenital vaginal septa, 349–350
- Contrast-enhanced CT, 396
- diverticulosis, 399
 - dysgerminoma, 311
 - ovarian vein thrombosis, 396
 - pelvic congestion syndrome, 394
- Cotyledon structure, 470, 472
- Crohn's disease, 396
- clinical manifestations, 401
 - differential diagnosis, 402
 - imaging findings, 401
 - value of imaging, 402
- Cystadenofibroma, 255–256
- Cystadenoma
- differential diagnosis, 254–255
 - features, 252
 - mucinous
 - on CT, 252, 253
 - on MRI, 253
 - papillary projections in, 253, 254
 - vs. serous cystadenoma, 252
 - in reproductive age, 252
 - serous, 252
- Cystocele, 420
- Cystourethrography, 425

D

- Defecography, 409
- Delayed post-contrast CT, ovarian cysts, 383
- DES-exposed uterus, 72
- Diethylstilbestrol (DES), 449–450
 - DES-exposed uterus, 72
- Diffuse adenomyosis, 53
- Diffuse ascites, 308

Diffuse leiomyomatosis

- macroscopic pathology, 78, 79
 - magnetic resonance imaging, 91
- Diffusion-weighted imaging (DWI), 293, 311, 316, 469, 478, 482
- endometrial stromal sarcomas, 216–217
 - leiomyosarcoma, 215
 - lymph node metastasis, 147, 149–150
 - magnetic resonance imaging, 297, 371–374
 - normal ovaries, 229
- Disseminated peritoneal disease, 305
- Distant vaginal metastases, 359
- Diverticulosis, 398–399
- Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), 353, 372
- Dysgenesis, 66, 67
- Dysgerminomas, 311, 312

E

- Ectopic pregnancy, 384
 - cause of, 392
 - in cervix, 392
 - differential diagnosis, 393
 - imaging findings, 393
 - value of imaging, 393–394
- Embryogenesis, urogenital female tract, 63
- Endodermal sinus tumor, 310, 311
- Endofascial defects, 416, 417
- Endometrial cancer
 - clinicopathology, 180
 - diagnosis, 182–183
 - epidemiology, 180
 - follow-up, 203
 - functional MRI assessment, 199
 - prognosis, 204
 - recurrence
 - MR imaging, 203
 - occurrence, 203
 - PET-CT, 204
 - treatment of, 204
 - risk factors, 180–182
 - staging
 - FIGO 2009 classification, 183
 - MR findings (*see* Magnetic resonance imaging (MRI))
 - stage I, 183
 - stage IA, 183
 - stage II, 184
 - stage III, 184
 - stage IV, 184
 - symptoms, 182–183
 - therapeutic approaches
 - adjuvant radiation therapy, 202–203
 - fertility-sparing treatment, 203
 - surgical approach, 201–202
 - types of, 180–182
 - World Health Organization classification, 180
- Endometrial carcinoma, 101, 314, 361
- Endometrial polyps, 97

- Endometrial stroma sarcoma (ESS), 101
 clinical presentation, 211
 components, 210
 imaging
 DWI, 216–217
 high-grade, 217–219
 low-grade, 217, 218
 lymph node metastases, 217
 ultrasonographic evaluation, 216
 undifferentiated uterine sarcoma, 219, 220
 mesenchymal origin, 211
 staging system, 212
 WHO classification, 210
- Endometrioid ovarian carcinomas, 304
- Endometrioids, 139
- Endometriomas, 306, 328–331, 387
- Endometriosis, 172, 325, 441, 451–452
 cysts, 328–331
 diagnosis of, 326
 etiology of, 326
 infiltration, 334
 MRI
 anterior rectum and sigmoid, 333, 336, 338
 cecum, ileum and appendix, 333, 336, 338
 checklist, 328
 endometriotic cysts/endometriomas, 328–331
 ESUR guidelines, 327
 indications, 327
 lateral and anterior pelvic wall, 333–337
 parametrium and peritoneum, 333–337
 pelvic phased-array coil, 327
 posterior fornix of upper vaginal wall, 331–334
 protocol, 327–328
 rare localizations, 338
 round ligaments, 333–337
 spatial resolution, 327
 special types and associated complications, 338
 urinary bladder, 331, 332
 uterine ligaments, 333–337
 vaginal filling with ultrasound gel, 327
 vaginal wall, 331–334
 vesicouterine pouch, 331, 332
 sonography, 326–327
 symptoms, 326
- Endometriosis genitalis interna, *see* Adenomyosis
- Enteroceles, 419
- EOC, *see* Epithelial ovarian cancer (EOC)
- Eiploic appendages, 400–401
- Epithelial ovarian cancer (EOC), 370
 borderline tumors
 differential diagnosis, 308
 histologic and cytogenetic features, 306
 imaging findings, 307–308
 mucinous, 307
 clear cell carcinomas, 305
 endometrioid carcinomas, 304
 high-grade serous epithelial cancer, 302, 304
 imaging findings of
 CT and MRI, 305
 differential diagnosis, 305–306
 low-grade serous ovarian cancer, 302, 304
 mucinous cancers, 304
 recurrent ovarian cancer, 308–310
- Epithelial tumors, 302
- Epithelioid leiomyosarcoma, 215
- ESGAR, 409, 411
- ESUR guidelines, 301, 327, 331, 409, 411, 412, 415, 417, 440
- External beam radiation therapy (EBRT)
 cervical cancer, 124, 157
 endometrial cancer, 202
- External pelvimetry, 458
- F**
- Fallopian tubes, 298, 392, 431, 438
 adrenal cortical rests, 235
 anatomical relationships, 225–226
 cancer, 288, 318–319
 congenital abnormalities, 235
 dilated, 385
 disorders of, 441–442
 in reproductive age, 227, 228
 and vascular supply, 232
- Familial ovarian cancers, 288
- Fast imaging employing steady-state acquisition (FIESTA), 468
- Fast imaging with steady-state precession (FISP), 468, 470, 474, 478
- Ferumoxtran-10-based contrast agents, 373
- Fibromas, 261–262
- Fibrothecoma, 311
- FIGO staging, *see* International Federation of Gynecology and Obstetrics (FIGO) system
- Fluoroscopic X-ray techniques, 408
- Focal adenomyosis of the uterus, 98
- Focal fat infarction, 401
- Fritz-Hugh–Curtis syndrome, 384
- Functional MRI, endometrial carcinoma, 199
- G**
- Gadolinium based contrast agents, 373
- Gartner duct cysts, 351
- Gd-enhanced MR imaging, 438
- Genomic profiling, 288
- Granulosa cell tumors, 266, 314
- Gynecological malignancies, 369
- H**
- Half-Fourier acquisition single-shot turbo spin echo (HASTE), 328
- Hammock hypothesis of DeLancey, 22
- Hematosalpinx, 393
- Hemorrhagic leiomyoma infarction, 105, 107, 390
- Hereditary breast-ovarian cancer syndrome (HBOC), 288
- Hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, 288

- Hiatus/muscle/organ (HMO), 418
- High-grade serous cancer
diffuse mesenterial involvement in, 295
in epithelium, 302, 304
- HSG, *see* Hysterosalpingography (HSG)
- Human chorionic gonadotropin (HCG), 290, 311
- Human papilloma virus (HPV)
cervical cancer
prevalence, 118
screening test, 119
vaccination, 119
infection, 354
- Human papilloma virus-positive tumors, 360
- Hydrosalpinx, 385
- Hydrosalpinx, 319, 391
- Hypercalcemia, 305
- Hyperintense peripheral cysts, 441
- Hyperprolactinemia, 439
- Hypoplasia, 444
- Hypoplastic T-shaped deformity, 450
- Hysterectomy, 364, 477, 482
- Hysterosalpingography (HSG), 441
arcuate uterus, 449
bicornuate uterus, 448
cycle considerations, 430
DES, 449
fallopian tubes, 431
limitations of, 435
pathological findings
Asherman syndrome, 432, 435
bilateral fallopian tube obstruction, 432, 433
endometrial polyps, 432, 434
SIN, 432
synechiae, 432, 434
septate uterus, 449
side effects and complications, 430–431
technical considerations, 430
uterus didelphys, 444, 445
- Hysteroscopic septoplasty, 448
- Hysteroscopy, cervical polyps, 171
- I**
- Immature teratomas, 311–313
- Infarcted leiomyoma, 94, 96
- Infertility, evaluation of
definition, 429
fallopian tubes, disorders of, 441–442
hysterosalpingography
cycle considerations, 430
fallopian tubes, 431
limitations of, 435
pathological findings, 432–435
side effects and complications, 430–431
technical considerations, 430
- MR imaging
indications, 437–438
limitations, 438
in postmenopausal women, 439
of postmenopausal women, 439
in reproductive-age women, 438
technical considerations, 438
ovulatory dysfunction, 439
pituitary adenoma, 439–440
polycystic ovarian syndrome, 440–441
sonohysterography, 435–437
sonohysterosalpingography, 435–437
uterine disorders
adenomyosis, 450
endometriosis, 451–452
leiomyoma, 450–451
MDA (*see* Müllerian duct anomalies (MDAs))
- Inguinal lymph node metastases, 301
- International Federation of Gynecology and Obstetrics (FIGO) system, 355, 370
endometrioid carcinoma grade 1 or 2, 181
IIIC ovarian cancer, 375, 376
IVA cervical carcinoma, 360
IVA squamous cell carcinoma, 356
ovarian cancer, 298–301
for vulvar cancer, 362
- International Ovarian Tumor Analysis (IOTA) group, 297
- Interstitial ectopic pregnancy, 393
- Intraperitoneal appendices, 397
- Intrauterine contraceptive device (IUCD), 384, 386
- Intrauterine growth restriction (IUGR), 481
- Intrauterine hematoma, 478, 480
- Intravenous tissue-specific contrast agents, 373
intravenous unspecific contrast agents, 373
- J**
- Juvenile type of granulosa cell tumor, 315
- K**
- Krukenberg tumors, 315, 317, 318
- L**
- Labial thrombophlebitis, 352
- Leiomyomas, 171, 319, 432, 450–451
benign tumors, 78, 210
clinical presentation, 80–81
CT appearance, 101–103
degenerative changes, 80
diagnostic imaging
anechoic cystic portions and degenerative changes, 86
computed tomography, 88
endoscopic procedures, 87
laparoscopy/hysteroscopy, 87
magnetic resonance imaging, 87–88
transvaginal ultrasound, 86, 87
epidemiology, 77–78
histopathology, 78–80
incidence, 77
macroscopic pathology, 78, 79
mass effect, 91

- monoclonal tumors, 78
 - MRI criteria, 92
 - necrosis, 80
 - pathogenesis, 78
 - patient's symptoms, 80
 - pregnancy-related hemorrhagic infarction, 80
 - quality of life, 81
 - reproductive factors, 78
 - steroid hormones, 77
 - treatment
 - ablation, 81–82
 - endometrial ablation, 82
 - hysterectomy, 82
 - indications, 81
 - magnetic resonance-guided focused ultrasound, 84
 - medical therapy, 81–82
 - menstrual bleeding, 82
 - progesterone receptor modulators, 82
 - surgical therapy, 82–83
 - UAE, 83, 103–108
 - vascular sign, 92
 - Leiomyosarcoma (LMS), 98
 - clinical presentation, 211
 - definition, 210
 - gynaecological sarcomas, 209
 - imaging
 - characteristics features, 213, 214
 - cytogenetic abnormalities, 213
 - Doppler findings, 213
 - DWI sequences, 215–216
 - epithelioid, 215
 - haematogenous spread, 215
 - MR, 213, 214
 - myxoid, 215
 - pelvic ultrasound, 213
 - PET-CT, 216
 - incidence, 211
 - mesenchymal origin, 211
 - staging system, 212
 - and undifferentiated uterine sarcomas, 222
 - Levator ani muscle, 416, 422–423
 - Liver metastases
 - CT, 153
 - MRI, 153
 - Low-grade serous ovarian cancer, 302, 304
 - Lymph node imaging
 - in benign and malignant
 - CT, 373–376
 - MRI, 373–376
 - indications
 - ADC, 371
 - CT, 370, 373
 - DCE-MRI, 372
 - DW-MRI, 371, 372
 - MRI, 371–373
 - PET-CT, 371, 372
 - PET-MRI, 371, 372
 - T2-weighted MRI, 371
 - risk-scoring systems, 370
 - Lymph node metastases
 - cervical cancer
 - contrast-enhanced CT image, 157
 - diffusion-weighted MR imaging, 147, 149–150
 - FDG-PET/CT vs. DWI, 151–152
 - metastatic spread, 146–147
 - PD-TSE images, 156
 - probability of, 121
 - surgical lymphadenectomy, 146–147
 - T1w TSE images, 156
 - whole-body FDG-PET, 150–151
 - in endometrial cancer, 184, 204
 - Lymphoma, 358–359, 363–364
 - cervical, 171
 - Lynch syndrome, 289
- M**
- Macroadenomas, 440
 - Maffucci's syndrome, 314
 - Magnetic resonance imaging (MRI)
 - abdominal and pelvic examinations, 33
 - adenomyosis
 - criteria, 98–99
 - differential diagnosis, 101
 - endometrial carcinoma, 101
 - growth patterns, 100
 - imaging characteristics, 100
 - locations, 100
 - adenosarcoma, 219, 221
 - adnexal masses
 - ADNEX MR score, 276, 277
 - evaluating risk of malignancy, 276, 277
 - histopathological diagnosis, 276–284
 - ovarian cysts (*see* Ovarian cysts)
 - pelvic, 274–276, 285
 - significance of, 274
 - simple rules by IOTA group, 275
 - with ultrasonographic patterns, 274–275
 - arcuate uterus, 449
 - bicornuate uterus, 448
 - bowel peristalsis, 32
 - cervical cancer
 - angulated image acquisition, 128, 131
 - cervicitis, 171–172
 - coil technique, 136
 - vs. computed tomography, 126–127
 - contrast enhancement of, 130–134
 - diffusion-weighted imaging, 131–133
 - dynamic contrast-enhanced, 133, 136
 - ectopic cervical pregnancy, 172
 - endometriosis, 172
 - findings after chemotherapy, 159
 - findings after radiotherapy, 160–161, 163–165
 - findings after surgery, 157–159, 161–162
 - imaging before radiotherapy, 155–157, 160–161
 - indications, 125
 - leiomyoma, 171
 - lymphoma, 171
 - malignant melanoma, 171

- Magnetic resonance imaging (MRI) (*cont.*)
- nabothian cysts, 169, 171
 - position of uterus, 128, 130
 - preoperative imaging, 155
 - protocol, 127–129, 133, 135–136
 - sensitivity and specificity, 125
 - vaginal infiltration, 128
 - vaginal opacification, 136–137
- DES, 450
- didelphys, 444–446
- diffusion-weighted imaging, 36–37
- dynamic contrast enhancement, 37
- endometrial cancer
- ADC values, 187–188
 - benign polyp, 187, 190
 - features of, 187–189
 - normal uterine anatomy, 187
 - protocol, 185–187
 - significance, 184–185
 - stage I disease, 188–195
 - stage II disease, 195–196
 - stage III disease, 197–200
 - stage IV disease, 197, 200–202
- endometrial stromal sarcoma
- high-grade, 217–219
 - low-grade, 217, 218
 - undifferentiated uterine sarcoma, 219, 220
- endometriosis, 451–452
- anterior rectum and sigmoid, 333, 336, 338
 - cecum, ileum and appendix, 333, 336, 338
 - checklist, 328
 - complications, 338
 - endometriotic cysts/endometriomas, 328–331
 - ESUR guidelines, 327
 - indications, 327
 - lateral and anterior pelvic wall, 333–337
 - parametrium and peritoneum, 333–337
 - pelvic phased-array coil, 327
 - posterior fornix of upper vaginal wall, 331–334
 - protocol, 327–328
 - rare localizations, 338
 - round ligaments, 333–337
 - spatial resolution, 327
 - types, 338
 - urinary bladder, 331, 332
 - uterine ligaments, 333–337
 - vaginal filling, ultrasound gel, 327
 - vaginal wall, 331–334
 - vesicouterine pouch, 331, 332
- fetus development, 32
- gadolinium-based contrast agents, 37–38
- gradient-echo sequences, 36
- hydronephrosis/renal malformations, 33
- infertility, evaluation of
- indications, 437–438
 - limitations, 438
 - in postmenopausal women, 439
 - in reproductive-age women, 438
 - technical considerations, 438
 - urinary tract abnormalities, 443
- intrauterine devices, 32
- leiomyomas, 451
- chemical shift imaging, 93
 - contrast-enhanced imaging studies, 90
 - cystic degeneration, 94
 - degenerative forms, 93–95
 - differential diagnosis, 96–98
 - of diffuse leiomyomatosis, 91
 - diffusion-weighted, 90
 - dynamic multiphase contrast-enhanced, 90
 - expansive growth patterns, 91
 - gadolinium-enhanced images, 90
 - haemorrhagic/red degeneration, 94
 - histologic subtypes, 93–95
 - hyaline degeneration, 94
 - intralesional calcifications, 95
 - localization, 91
 - mass effect, 91
 - myxoid degeneration, 94
 - polyfibroid uterus, 90
 - rim calcification, 96
 - spectral fat suppression, 93
 - T1- and T2-weighted sequences, 89
- leiomyosarcoma, 213, 214
- lymph node imaging
- in benign and malignant lymph nodes, 373–376
 - indications and value of imaging, 371–373
- multiplanar high-resolution nonfat-saturated T2W sequences, 36
- ovarian cancer, 291, 295, 296
- borderline serous cystadenoma, 281
 - brenner tumors, 263–266
 - BT, 307
 - cystadenofibroma, 255–256
 - cystadenoma, 252–254
 - cyst with papillary projections, 279–282
 - dysgerminoma, 311, 312
 - epithelial ovarian cancer, 305
 - fallopian tube cancer, 319
 - FIGO classification system, 298–301
 - immature teratoma, 312
 - invasive cystadenocarcinoma, 282
 - lymphoma, 284
 - lymphomas, 316
 - mature cystic teratoma, 279
 - mature teratoma (*see* Teratoma)
 - multilocular cyst, 279
 - nonsimple cyst, 279
 - prediction of resectability, 301
 - purely solid mass, 283
 - recurrence, 308, 310
 - serous benign cystadenoma, 277, 280
 - sex cord-stromal tumors (*see* Sex cord-stromal tumors)
 - struma ovarii, 260
 - value of imaging, 301
- ovaries
- normal peri- and postmenopausal, 231
 - ovarian maldescent, 235–236
 - in reproductive age, 227–229
 - uterine axis and ovarian fossa, 226
- patient preparation and positioning, 32–33

- pelvic floor (*see* Pelvic floor, MRI)
- pelvic pain disorders, 382
- in pelvis, 274–276, 285
- phased-array coils, 32, 33
- of placenta
 - cell-free fetal DNA, 482
 - cotyledons, 470, 472
 - diffusion restriction, 482
 - diffusion-weighted placental imaging, 469
 - drawbacks, 468
 - flat and smooth surface, 470, 471
 - gadolinium-based contrast agents, 469
 - GRAPPA with iPAT factor 2, 469
 - gravid uterus, 470
 - homogeneous, 470, 471
 - invasive placental processes, 468
 - IUGR, 481
 - myometrium, 470, 472, 473
 - normal placental septa, 470, 472
 - parameters, 468, 469
 - patients positioning, 468
 - phased-array coil, 468
 - placenta abruption, 477–480
 - placental adhesive disorders, 474–477
 - placental-myometrial interface, 470
 - placental size, 470
 - placenta-myometrium interface, 470
 - placenta variants, 470, 473–475
 - second trimester, 470
 - solid placental masses, 480–481
 - steady-state free-precession sequences, 468
 - 3 Tesla (T) system, 468
 - third trimester, 470
 - T1 and T2-weighted fast spin-echo sequence, 469
- in pregnancy, 32
- protocols, 33–36
- rectal/vaginal opacification, ultrasound gel, 32
- septate uterus, 449
- spasmolytic medication, 33
- T1- and T2-weighted imaging, 36
- unicornuate, 444
- uterus didelphys, 445
- vaginal and vulvar diseases, 343, 353–354
 - axial T1WI, 348
 - dynamic contrast-enhanced subtracted MR image, 347
 - fibromuscular wall, 347
 - primary vaginal carcinoma, 357
 - protocol, 346
 - T2WI, 347
 - vaginal cuff diseases, 365, 366
 - vaginal mucosa, 346
 - vulval cancer, 362–364
- Magnetic resonance (MR) pelvimetry
 - contraindications, 459–460
 - last trimester with small pelvic dimensions, 460, 462
 - pelvimetric diameters, 460, 461
 - protocol, 460
 - RCT, 463
 - reference values, 463
 - safety issues, 459–460
 - secondary cesarean section and retroverted uterus, 460–461
 - soft-tissue structures, 459
- Magnetic resonance venogram (MRV), 394
- Malignant germ cell tumors
 - ascites, 310
 - dysgerminomas, 311, 312
 - endodermal sinus tumors, 310, 311
 - immature teratomas, 311–313
 - malignant transformation in benign teratoma, 312–313
- Malignant melanoma, 171
- Malignant teratomas, *see* Immature teratomas
- Malignant transformation in benign teratoma, 312–313
- Massive ovarian edema, 392
- Mature teratoma, 313
- Mayer–Rokitansky–Kuster–Hauser (MRKH) syndrome, 350, 444
- Melanoma, 357–358, 362
- Mesonephric cyst, 351
- Metaplasia theory, 326
- Metastasis, cervix, 170
- Metroplasty, 449
- Michaelis’s rhomboid, evaluation of, 458
- Microadenoma, 439–440
- MR Adnex score, 293
- MR defecography, 421, 422
- MR-guided high-intensity-focused ultrasound (MR-HIFU), 482
- Mucinous adenocarcinoma, 139, 305
- Mucinous carcinomas, 180, 181
- Mucinous epithelial ovarian cancer, 304
- Müllerian duct anomalies (MDAs), 348
 - arcuate uterus, 449
 - axial T1-weighted sequences, 66
 - bicornuate, 447–448
 - class I anomalies (*see* Dysgenesis)
 - class II anomalies (*see* Unicornuate uterus)
 - class III anomalies (*see* Uterus didelphys)
 - class IV anomalies (*see* Bicornuate uterus)
 - class VI anomalies (*see* Arcuate uterus)
 - class VII anomalies (*see* DES-exposed uterus)
 - clinical presentations, 62–63
 - didelphys, 444–446
 - diethylstilbestrol related, 449–450
 - embryogenesis, 62, 63
 - epidemiology, 61–62
 - forms of, 62
 - hypoplasia/agenesis, 444
 - hysterosalpingography, 64
 - infertility, 61
 - MR imaging protocol, 65
 - pathology, 63–64
 - pregnancy loss, 62
 - prevalence, 61
 - repeated miscarriage, 62
 - septate uterus, 448–449
 - symptoms, 442–443
 - unicornuate, 444, 445
- Müllerian organogenesis, 46
- Müllerian tumour, malignant, 211

- Multidisciplinary consensus conferences (MDC), 301
 Myometrial contractions, 96
 Myxoid leiomyoma, 95
 Myxoid leiomyosarcoma, 215
- N**
 Nabothian cysts, 169, 171
Neisseria gonorrhoeae infection, 171, 384
 Neo-adjuvant chemotherapy (NACT), 370
 Nephrogenic systemic fibrosis (NSF), 38
 Neuroendocrine cervical carcinoma, 140
 Neuroendocrine tumors, 120
 cervix, 182
 endometrial, 182
 Nonepithelial ovarian malignancies
 malignant germ cell tumors, 310–313
 ovarian lymphoma, 315–317
 sex-cord stromal tumors, 314–315
 Non-Hodgkin lymphoma (NHL), 363
 Nonoptimally resectable ovarian cancer, 302
 Non-squamous cell carcinomas
 adenocarcinomas, 357
 lymphoma, 358–359
 melanoma, 357–358
 sarcomas, 259, 358
 Normal female pelvis, 344
- O**
 Ollier's disease, 314
 Omental implants, 296
 Ovarian carcinoma, 370
 clinical presentation, 290
 epidemiology, 288
 fallopian tube cancer, 318–319
 familial/hereditary, 288–289
 genomic profiling, 288
 imaging findings
 in adnexal mass, 290
 ancillary findings, 291
 ascites, 297
 bilateral ovarian cancer, 290, 291
 calcifications in, 291, 292
 CT, 291
 DCE, 292
 DWI, 292
 MR Adnex score, 293
 MRI, 291, 296
 papillary projections, 291, 292
 peritoneal carcinomatosis, 294–297
 PET/CT, 293–294
 psammoma bodies, 291
 time-intensity curves, 292, 293
 pathways of spread, 297–298
 risk factors, 288
 screening for, 289
 staging of
 CT and MRI, 298–301
 FIGO, 298
 resectability prediction, 301–302
 TNM, 298
 tumorigenesis of, 289
 tumor markers, 290
 tumor types
 clinicopathological and radiological
 characteristics of, 302, 303
 epithelial tumors (*see* Epithelial ovarian cancer)
 nonepithelial (*see* Nonepithelial ovarian malignancies)
 ovarian metastases, 317–318
 Ovarian cysts
 differential diagnosis, 384
 imaging findings, 382–383
 non-physiological cysts, rupture of, 382
 paraovarian cysts, 248–249
 PCOS (*see* Polycystic ovarian syndrome (PCOS))
 peritoneal inclusion cysts, 249–250
 physiology
 classification, 247
 CT and MRI, 248
 differential diagnosis, 248
 follicles developmental stages, 247
 functional cysts, 247
 prevalence, 247
 transvaginal sonography, 247–248
 theca lutein cysts, 250–251
 value of imaging, 384
 Ovarian hyperstimulation syndrome, 250
 Ovarian lymphoma, 315–317
 Ovarian masses, 96
 Ovarian torsion
 age groups, 389
 causes, 389
 diagnostic value, 392
 differential diagnosis, 391–392
 hemorrhagic infarction, 390
 imaging findings, 390–391
 partial or intermittent, 390
 in postmenopausal women, 390
 predisposing factors, 390
 during pregnancy, 390
 in women, 390
 Ovarian vein thrombosis, 396
 Ovaries
 anatomical relationships, 226–227
 congenital abnormalities
 accessory/supernumerary ovaries, 234–235
 streak gonads, 234, 236
 developmental origin, 233
 migration, 233–234
 normal peri- and postmenopausal
 in CT, 230–231
 mild hyperplasia, 230
 in MRI, 231
 pelvic free fluid, 231–232
 stromal atrophy, 230
 ovarian maldescent
 associated with uterine malformation, 235, 237
 in ectopic position, 235

- incidence, 235
 - location of, 235
 - pelvic free fluid, 231–232
 - in reproductive age
 - features, 227
 - imaging findings, 227–230
 - normal ovarian volume, 227
 - surgical transposition
 - differential diagnosis, 238
 - imaging findings, 236–238
 - lateral and medial, 236
 - sites of, 236
 - vascular supply, 232–235
 - Ovulatory dysfunction, 439
- P**
- PAD, *see* Placenta adhesive disorders (PAD)
 - Paget disease, 360
 - Palpable nodule, 336
 - Palpation of pelvis, 459
 - Parametrial endometriosis, 334
 - Paraneoplastic syndromes, 290
 - Paraovarian cysts
 - CT and MRI imaging, 248–249
 - differential diagnosis, 249
 - features, 248
 - origin, 248
 - Para-tubal cysts, 390
 - PCL, *see* Pubococcygeal line (PCL)
 - Pelvic actinomycosis, 386
 - Pelvic congestion syndrome
 - asymptomatic hematuria, 394
 - differential diagnosis, 394–395
 - dilated veins, 394
 - imaging findings, 394, 395
 - obstructing anatomic anomalies, 394
 - pathogenesis of, 394
 - prevalence of, 394
 - value of imaging, 396
 - Pelvic floor, MRI
 - anterior compartment, 420–421
 - in asymptomatic females, 423–424
 - bony pelvis, 415
 - dysfunction, 408
 - etiology, 408
 - risk factors, 408
 - imaging techniques, 408
 - indications, 409
 - levator ani muscle, 422–423
 - middle compartment, 421
 - muscles and ligaments, 415–417
 - organ opacification, 440
 - pathological findings and grading, 418–419
 - patient instruction, 409
 - patient positioning, 440
 - patient preparation, 409
 - posterior compartment, 421–422
 - reference lines, 417–418
 - sequence protocols
 - defecation disorder, 414
 - dynamic MRIs, 410, 411
 - ESUR/ESGAR, 412
 - midsagittal plane, 411
 - partial prolapse of posterior vaginal wall, 414
 - stool outlet obstruction, 413
 - T2W imaging, 410
 - static and dynamic MRI sequences, 408
 - value of MRI vs. conventional techniques, 424–425
 - Pelvic infection, 430
 - Pelvic inflammatory disease (PID), 384, 388, 393, 441
 - Pelvic organ prolapse (POP), 408, 409, 415, 418, 419, 424
 - Pelvic pain disorders
 - differential diagnosis of, 381
 - gynecological causes of
 - ectopic pregnancy, 392–394
 - hydrosalpinx, 385
 - ovarian cysts, 382–384
 - ovarian torsion, 389–392
 - PID, 384
 - tubo-ovarian abscess, 385–389
 - nongynecological causes of
 - appendicitis, 397–398
 - colonic diverticulosis, 398–399
 - Crohn's disease, 401–402
 - epiploic appendages, 400–401
 - ovarian vein thrombosis, 396
 - pelvic congestion syndrome, 394–396
 - rectus sheath hematoma, 402–403
 - relative frequency of imaging, 382
 - Pelvic sidewall invasion, 300
 - Pelvic varices, 394, 395
 - Pelvic venous incompetence (PVI), *see* Pelvic congestion syndrome
 - Pelvic wall endometriosis, 334
 - Pelvimetry, 455
 - clinical methods of
 - external pelvimetry, 458
 - Michaelis's rhomboid, evaluation of, 458
 - palpation of pelvis, 459
 - diagnosis, abnormal length of labor, 457
 - inadequate progression
 - fetal factors, 458
 - inefficient contraction, 458
 - maternal factors, 457–458
 - indications for
 - arrest of labor, 464
 - breech presentation, 463–464
 - pelvic shape, clinically conspicuous abnormalities of, 464
 - spontaneous delivery, maternal preference for, 463–464
 - status post pelvic fracture, 464
 - magnetic resonance pelvimetry
 - contraindications, 459–460
 - last trimester with small pelvic dimensions, 460, 462
 - pelvimetric diameters, 460, 461
 - protocol, 460

- Pelvimetry (*cont.*)
 reference values, 463
 safety issues, 459–460
 secondary cesarean section and retroverted uterus, 460–461
 soft-tissue structures, 459
 primary vs. secondary cesarean section, 456
 RCT, 463
- Perineal body, 2, 3
 anatomy and clinical relevance, 26–29
 connective tissue structures and muscles, 26, 27
 dynamic transperineal ultrasound, 26
 fibromuscular, 27
 intralevatoric side, 26
 rupture, 28, 29
- Peritoneal carcinomatosis, 288, 294–297
 characterization, 297
 CT, 295
 high-grade serous cancer, 295
 omental implants, 296
 peritoneal implants, 294, 295
 peritoneal parietal and visceral surfaces, 294
 PET/CT, 297
 superiority of MRI, 296
- Peritoneal implants, 294–296, 299
- Peritoneal inclusion cysts
 clinical presentation, 249
 on CT, 249
 differential diagnosis, 250
 features, 249
 on MRI, 249, 250
- Peritoneal tuberculosis, 387, 388
- Peritoneocele, 419, 421
- Peutz-Jeghers syndrome, 119, 314
- Phlegmon, 397, 399
- PID, *see* Pelvic inflammatory disease (PID)
- Pituitary adenoma, 439–440
- Placenta
 abruption, 477–480
 magnetic resonance imaging
 cell-free fetal DNA, 482
 cotyledons, 470, 472
 diffusion restriction, 482
 diffusion-weighted placental imaging, 469
 drawbacks, 468
 flat and smooth surface, 470, 471
 gadolinium-based contrast agents, 469
 GRAPPA with iPAT factor 2, 469
 gravid uterus, 470
 homogeneous, 470, 471
 invasive placental processes, 468
 IUGR, 481
 myometrium, 470, 472, 473
 normal placental septa, 470, 472
 parameters, 468, 469
 pathologic conditions of, 468
 patients positioning, 468
 phased-array coil, 468
 placenta abruption, 477–480
 placental adhesive disorders, 474–477
 placental-myometrial interface, 470
 placental size, 470
 placenta-myometrium interface, 470
 placenta variants, 470, 473–475
 second trimester, 470
 solid placental masses, 480–481
 steady-state free-precession sequences, 468
 3 Tesla (T) system, 468
 third trimester, 470
 T2-weighted fast spin-echo sequence, 469
 T1-weighted sequences, 469
- Placenta accreta, 474, 476, 477
- Placenta adhesive disorders (PAD), 470
 dynamic contrast-enhanced imaging, 476–477
 NPV, 477
 placenta accreta, 474, 476, 477
 placenta increta, 474
 placenta percreta, 474, 476, 477
 placenta previa, 473–477
 PPV, 477
 S1 and S2, 477
 sonography vs. MRI, 477
 tenting of bladder, 474
 uterine bulging, 474
- Placenta diffusa, 473
- Placenta increta, 474
- Placenta membranacea, 473
- Placenta percreta, 474, 476, 477
- Placenta previa, 473–477
- Platypeloid pelvis, 458
- Polycystic ovarian syndrome (PCOS), 266, 440–441
 characteristics, 251
 clinical presentations, 251
 differential diagnosis, 252
 in MRI, 251
 ultrasound, 251
- Polypos, 171
- POP, *see* Pelvic organ prolapse (POP)
- Potter's syndrome, 314
- Primary debulking surgery (PDS), 370
- Primary lymphoma, 358
- Primary non-Hodgkin lymphoma, 363
- Primary vaginal carcinoma, 354–357
 lymph node drainage, 356–357
 MRI findings, 355–356
 recurrence and complications, 357
- Prolactinoma, 439
- Prolactin-producing adenoma, 439
- Prophylactic salpingo-oophorectomy, 289
- Prostate, lung, colorectal, ovarian (PLCO) cancer screening trial, 289
- Psammoma bodies, 291, 304
- Pseudomyxoma peritonei with cystic peritoneal implants, 304
- Pseudo-small-bowel obstruction pattern, 308
- Pubococcygeal line (PCL), 417–419, 421, 422
- Puerperal ovarian vein thrombosis (POVT), 396
- Pulmonary metastases, chest CT, 153
- Pyosalpinx, 385

Q

Quantification staging system of pelvic organ prolapsed (qPOP), 418, 424

R

Radiation exposure, 430–431
 Rapid acquisition with relaxation enhancement (RARE), 468
 Rare benign tumors, 171
 Rectocele, 419, 421
 Rectus sheath hematoma, 402–403
 Recurrent ovarian cancer
 ascites, 308
 differential diagnosis, 309
 imaging findings, 308–309
 lymph node metastases, 308
 pelvic relapse, 308
 serum tumor markers, 308
 small- and large-bowel obstruction, 308
 value of imaging, 309–310
 Response evaluation criteria in solid tumors (RECIST)
 guidelines, 140
 Retrocervical endometriosis, 337
 Retrograde menstruation, 326
 Retroperitoneal lymphadenopathy, 299
 Retroplacental hematomas, 478
 Retzius space, 420
 Ruptured ovarian cysts, 391

S

Sacruterine ligaments, 416, 421
 Salpingitis, 385
 Salpingitis isthmica nodosa (SIN), 432
 Sarcomas, 358, 359
 Sclerosing stromal cell tumors, 266
 Secondary non-Hodgkin lymphoma (NHL), 363
 Secondary vaginal malignancies, 359–362
 Segmental omental infarction, 400
 Sentinel lymph node, 123
 Septate uterus, 71–72, 448–449
 Serous carcinomas, 180, 181
 Serous cystadenomas, 390
 Sertoli-Leydig cell tumors, 266, 314–316
 Serum alpha-fetoprotein (AFP), 290
 Serum lactate dehydrogenase (LDH), 290
 Sex cord-stromal tumors, 314–315, 318
 classification, 261
 components, 260–261
 fibroma and thecoma, 261–262
 functioning ovarian tumors, 266
 sclerosing stromal tumor, 262–263
 Sigmoid colon wall invasion in CT, 300
 Sigmoid diverticulitis, 399
 Silent killer, *see* Ovarian carcinoma
 Single-shot fast spin echo (SSFSE), 328
 Small-bowel obstruction, 308
 Small-cell cervical cancer, 120

Smooth muscle tumour of uncertain malignant potential (STUMP), 210
 Smooth muscle tumours, 210
 Solid dysgerminomas, 311
 Solid placental masses, 480–481
 Sonography, 382, 391, 392
 arcuate uterus, 449
 bicornuate uterus, 448
 endometriosis, 326–327
 uterus didelphys, 445
 Sonohysterography, 435–437
 leiomyoma, 451
 Sonohysterosalpingography, 430, 451
 accuracy, 437
 cycle considerations, 436
 hydrosalpinges, 435, 437
 limitations of, 437
 side effects and complications, 437
 technical considerations, 436–437
 Squamous cell carcinoma (SCC), 119, 139, 153, 354, 360
 Squamous intraepithelial lesion (SIL), 118
 Stromal tumors, 318
 Subamniotic hematomas, 478
 Subchorionic hematomas, 478
 Succenturiate lobe, 473
 Succenturiate placenta, 473
 Supplementary abdominal ultrasound, 327
 Suspected appendicitis, 397
 Swyer syndrome, 311
 Synechia, 432, 434

T

Teratoma, 383
 age factor, 256
 classification, 256
 mature cystic teratoma
 complications, 256–257
 CT findings, 257
 differential diagnosis, 258–259
 with fat, 256, 258, 259
 germ cell layers, 256
 MRI findings, 257–258
 unilocular cystic lesions, 256
 monodermal, 260
 Theca lutein cysts
 CT findings, 250, 251
 development, 250
 differential diagnosis, 250–251
 MRI findings, 250
 Thecomas, 261–262
 Three dimensional dynamic contrast-enhanced
 images, 293
 vaginal and vulvar diseases, 346
 Thyroid hormones, 266
 Tissue injury and repair (TIAR) theory, 326
 TOA, *see* Tubo-ovarian abscess (TOA)
 Transabdominal ultrasound, 436
 Transient myometrial contraction, 54, 55

- Transient uterine contraction, 97
 Transvaginal sonography, 436
 Transvaginal ultrasound, leiomyoma, 451
Trichomonas vaginalis, 171
 Tubal disorders, 441
 Tuberculous peritonitis, 387
 Tubo-ovarian abscess (TOA), 384, 391, 442
 causes, 386
 differential diagnosis, 387–388
 imaging findings, 386–387
 in postmenopausal women, 386
 value of imaging, 388–389
 Turbo spin echo (TSE), 327
 Turner syndrome, 311
 T1-weighted (T1WI) images, 353, 373, 386, 390, 469
 Crohn's disease, 401
 ectopic pregnancy, 393
 endometriosis, 328, 331, 334
 epiploic appendages, 400
 fastspoiled gradient-echo sequences, 460
 lymph node imaging, 372
 melanomas, 358
 pelvic congestion syndrome, 394
 rectus sheath hematoma, 402
 vaginal and vulvar diseases, 346, 348
 T2-weighted (T2WI) images, 349, 353, 355, 371, 385, 386, 390
 ectopic pregnancy, 393
 endometriosis, 328, 332, 338
 epiploic appendages, 400
 fast spin-echo sequence, 469
 half-Fourier RARE, 478
 lymph node imaging, 372
 ovarian vein thrombosis, 396
 pelvic congestion syndrome, 394
 rectus sheath hematoma, 402
 spin-echo sequences, 459
 turbo spin-echo sequences, 460
 vaginal and vulvar diseases, 346
 Twin-to-twin transfusion syndrome (TTTS), 482
- U**
 Ulcerative colitis, 402
 Ultrasmall superparamagnetic iron oxide particles (USPIO), 373
 Ultrasonography
 adnexal masses, 274–275
 cervical cancer, 170
 endometrial stromal sarcomas, 216
 Ultrasound, 468, 477, 478, 480, 482
 acute appendicitis, 398
 Umbilical metastasis, 301
 Unicornuate uterus, 67, 68, 444, 445
 Urethral suspension ligaments, 417
 Uterine anomalies, 429
 Uterine artery embolization (UAE), 83
 for adenomyosis, 104
 coaxial advanced microcatheters, 104
 on fertility, 103
 local anesthesia, 104
 MR imaging, 105–108
 postprocedural management, 104
 subserosal pedunculated and intraligamentous leiomyoma, 103
 symptomatic leiomyomas, 103
 uterine fibroid sloughing, 105, 107
 Uterine cervix
 CT, 56, 57
 dynamic enhancement patterns, 57
 MRI, 57, 58
 Müllerian ductal fusion, 58
 nabothian cysts, 57, 58
 plicae palmatae, 58
 zonal anatomy, 57
 Uterine contractions, 96–97
 Uterine corpus
 CT
 endometrial thickening, 50
 endometrium, 49, 50
 ovarian mucinous cystadenoma, 49, 50
 uterine enhancement pattern, 49, 51
 diagnostic tests, 49
 MRI
 apparent diffusion coefficient, 56
 blood oxygenation level dependent MRI, 56
 endometrial discharge, 56
 exogenous hormonal replacement, 54
 menstrual cycle, 56
 during menstrual phase, 53
 patient age, 54
 during proliferative phase, 53
 with retroverted and retroflexed uterus, 51, 52
 tissue blood flow, 56
 uterine zonal anatomy, 51
 reproductive life, 51
 Uterine fibroma, 311
 Uterine hypoplasia, 444
 Uterine leiomyomas
 benign tumors, 78
 clinical presentation, 80–81
 CT appearance, 88, 101–103
 degenerative changes, 80, 86
 diagnostic imaging
 anechoic cystic portions, 86
 endoscopic procedures, 87
 laparoscopy/hysteroscopy, 87
 transvaginal ultrasound, 86, 87
 epidemiology, 77–78
 histopathology, 78–80
 incidence, 77
 macroscopic pathology, 78, 79
 mass effect, 91
 monoclonal tumors, 78
 MRI criteria, 87–88, 92
 necrosis, 80

- pathogenesis, 78
 - patient's symptoms, 80
 - pregnancy-related hemorrhagic infarction, 80
 - quality of life, 81
 - reproductive factors, 78
 - steroid hormones, 77
 - treatment
 - ablation, 81–82
 - endometrial ablation, 82
 - hysterectomy, 82
 - indications, 81
 - magnetic resonance-guided focused ultrasound, 84
 - medical therapy, 81–82
 - menstrual bleeding, 82
 - progesterone receptor modulators, 82
 - surgical therapy, 82–83
 - UAE, 83
 - vascular sign, 92
 - Uterine ligaments, 333–337
 - Uterine peristalsis, 54
 - Uterine sarcomas
 - adenosarcoma (*see* Adenosarcoma, uterine sarcomas)
 - adjuvant chemotherapy, 222
 - carcinosarcoma, 211
 - clinical presentation, 211
 - diagnosis, 211
 - epidemiology, 209
 - ESS (*see* (Endometrial stroma sarcoma (ESS)))
 - evaluation of, 213
 - FIGO staging, 211–212
 - imaging
 - computed tomography, 213
 - magnetic resonance imaging, 213
 - significance of, 212
 - ultrasound, 213
 - malignant, 211
 - prognostic factors, 222
 - recurrence, 222
 - rhabdomyosarcoma, 211
 - smooth muscle tumours, 210 (*see also* Leiomyosarcoma)
 - standard of care, 222
 - systematic lymphadenectomy, 222
 - WHO classification, 209–210
 - Uterosacral ligaments, 333–337, 416
 - Uterovaginal anomalies, 443
 - Uterus
 - adenomyosis (*see* Adenomyosis)
 - arterial vasculature, 47, 48
 - bilateral serous ovarian cystadenomas, 47, 49
 - congenital malformations (*see* Müllerian duct anomalies)
 - embryonic development, 45–49
 - imaging techniques, 45
 - multidetector CT, multiplanar reformations, 45
 - pathologies, 45
 - patient evaluation, 45
 - zonal anatomy, 45–47
 - Uterus-conserving surgery, 105–108
 - Uterus didelphys, 67, 69–70, 444–446, 448
- V**
- Vaccine, HPV, 119
 - Vaginal agenesis, 350
 - Vaginal atresia, 350
 - Vaginal brachytherapy (VBT), endometrial cancer, 202
 - Vaginal cuff disease, 363–366
 - Vaginal cysts
 - bartholin gland cyst, 351–352
 - bartholinitis, 351
 - Gartner duct cysts, 351
 - MRI, 350
 - Vaginal diseases
 - benign conditions, vaginal cysts, 350–352
 - congenital anomalies
 - congenital vaginal septa, 349–350
 - imperforate hymen, 349
 - vaginal agenesis, 350
 - CT, 345–346
 - embryonic development and normal anatomy, 343–345
 - foreign bodies, 365, 367
 - malignant neoplasms
 - non-squamous cell carcinomas, 357–359
 - primary vaginal carcinoma, 354–357
 - secondary vaginal malignancies, 359–362
 - MRI, 343
 - axial T1WI, 348
 - dynamic contrast-enhanced subtracted MR image, 347
 - fibromuscular wall, 347
 - protocol, 346
 - T2WI, 347
 - vaginal mucosa, 346
 - post-radiation changes, 353
 - vaginal cuff disease, 363–366
 - vaginal fistulas, 352–353
 - vaginal infections, 352
 - Vaginal ultrasound, 326
 - Valsalva maneuver, 440
 - Vasa previa, 473
 - Vesicouterine pouch, endometriosis of, 331, 332
 - Vulvar disea Vulvar diseases ses
 - benign conditions, vaginal cysts, 350–352
 - cancer, 360, 362–364
 - congenital anomalies
 - congenital vaginal septa, 349–350
 - imperforate hymen, 349
 - vaginal agenesis, 350
 - CT, 345–346
 - embryonic development and normal anatomy, 343–345
 - genital traumatic injuries, 352

Vulvar disease Vulvar diseases see (*cont.*)

malignancies

- aggressive angiomyxoma, 363, 365
- lymphoma, 362–363
- melanoma, 362
- vulval cancer, 360, 362

MRI, 343

- axial T1WI, 348
- dynamic contrast-enhanced subtracted
 - MR image, 347
- fibromuscular wall, 347
- protocol, 346
- T2WI, 347
- vaginal mucosa, 346

- post-radiation changes, 353
 - vulvar infections, 352
 - vulvar thrombophlebitis, 352
- Vulvar edema, 352
- Vulvar infections, 352
- Vulvar thrombophlebitis, 352

W

- Wunderlich syndrome, 445, 446

Y

- Yolk sac tumors, 311